LGND Q2 2025 Earnings — Ligand Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

LGNDLigand Pharmaceuticals Incorporated

$4B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$48M+14.7% YoY

Gross Profit

$45M93.9% margin

Operating Income

$8M17.7% margin

Net Income

$5M10.2% margin

EPS (Diluted)

$0.24

QoQ Revenue Growth

+5.1%

Cash Flow

Operating Cash Flow

$16M

Free Cash Flow

$16M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$949M

Total Liabilities

$120M

Stockholders' Equity

$829M

Cash & Equivalents

$68M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$48M	$42M	+14.7%
Gross Profit	$45M	$57M	-21.3%
Operating Income	$8M	-$19M	+144.2%
Net Income	$5M	-$52M	+109.3%

Revenue Segments

Royalty

$36M38%

Intangible Royalty Assets

$30M31%

Kyprolis

$9M9%

Material Sales, Captisol

$8M9%

Financial Royalty Assets

$6M7%

Rylaze

$3M3%

Teriparatide Injection

$2M2%

Evomela

$1M2%